CognitOss Breakthrough Therapy Discovered to Treat Chronic Osteomyelitis

CognitOss, discovered by Locate Bio, for the treatment of chronic osteomyelitis. The device is inits development stage for the treatment of chronic osteomyelitis.

CognitOssis a fully resorbable bone graft built with best-in-class bone healing properties and a proprietary dual-phasic release of antibiotics will provide a bolus release at the site of the infection by preventing re-infection through a further controlled release. It is used as an adjuvant to oral or intravenous antibiotics to prevent colonisation of the graft material.

CognitOss expands the capabilities of the bone graft with a new reactive antibiotic release mechanismreleasinghigher levels of antibiotic in the presence of infection. In addition, it offers the surgeons a single surgical procedure alternative.

Osteomyelitis is an inflammatory infection of the bone which is generally caused by bacteria. The current standard treatment available for chronic osteomyelitis is surgical debridement, long-term, and high-dose administration of antibiotics. Moreover, for larger defectsbone grafting is the procedure which often requires a second surgical process to remove the non-resorbable bone graft.

US Food and Drug Administration (FDA)has granted Breakthrough Device Designation for CognitOss designed for the treatment of chronic osteomyelitis.